Jiří Mayer

Laboratory of myeloid leukemia biology

Head: Jiří Mayer
Brno node

Mayer.Jiri@fnbrno.cz
website of the Institute

HOME INSTITUTION

Faculty of Medicine MU

RESEARCH PROGRAMME(S)

RP 3 - Biomarkers of cancers and cancer diagnostics
RP 5 - Translational oncology: Verification clinical studies of the proof-of-concept type

The leukemic stem cell is the key to curing leukemia.

FOCUS OF RESEARCH
SELECTED PUBLICATIONS
EXPERTISE AND TECHNOLOGY
COLLABORATION WITHIN THE NICR
COLLABORATION WITH INFRASTRUCTURES
  • Mission: To identify and eradicate the leukemic stem cells behind the onset and relapse of leukemias.
  • Vision: To find new treatment options for patients with the most serious hematologic malignancies.

Our main goal is to characterize leukemic and normal stem cells in patients with acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) using single-cell and other advanced techniques. This characterization is intended to improve prognostication and monitoring of minimal residual disease. The expected outcome is to provide an easy-to-apply procedure (using flow cytometry and standard molecular analyses) for the detection and quantification of malignant and normal stem cells. In this way, we aim to improve the stratification and follow-up of patients from diagnosis to disease progression.

Read more
SELECTED PUBLICATIONS
  • Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, Martinez-Lopez J, Vestergaard H, Ehrencrona H, Machová Poláková K, Olsson-Strömberg U, Ossenkoppele G, Berger MG, Etienne G, Dengler J, Brümmendorf TH, Burchert A, Réa D, Rousselot P, Nicolini FE, Hofmann WK, Richter J, Saussele S; EURO-SKI Investigators: The european stop tyrosine kinase inhibitor trial (euro-ski) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission. J Clin Oncol, 2024, in print. DOI: 10.1200/JCO.23.01647
  • Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M: Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era-analysis of the European LeukemiaNet Blast Phase Registry. Leukemia, 2024, in print. DOI: 10.1038/s41375-024-02204-y
  • Žáčková D, Semerád L, Faber E, Klamová H, Stejskal L, Bělohlávková P, Karas M, Cmunt E, Černá O, Procházková J, Čičátková P, Kvetková A, Horňák T, Skoumalová I, Srbová D, Šálek C, Buffa D, Voglová J, Jurček T, Folta A, Ježíšková I, Žižková H, Machová Poláková K, Papajík T, Žák P, Jindra P, Svobodník A, Štěpánová R, Mayer J: Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia, 2024, 38, 893-897. DOI: 10.1038/s41375-024-02215-9
  • Hornak T, Mayer J, Cicatkova P, Semerad L, Kvetkova A, Klamova H, Faber E, Belohlavkova P, Karas M, Stejskal L, Cmunt E, Cerna O, Srbova D, Zizkova H, Vrablova L, Skoumalova I, Voglova J, Jurkova T, Chrapava M, Jurcek T, Jeziskova I, Jarosova M, Machova Polakova K, Papajik T, Zak P, Jindra P, Zackova D: De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tarosine kinase inhibitors. Am J Hematol, 2024, 763-766. DOI: 10.1002/ajh.27229
  • Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, Robak T, Kantarjian HM, Novák J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva L, Demeter J, Griffiths EA, Yee KWL, Issa JJ, Bewersdorf JP, Keer H, Hao Y, Azab M, Döhner H: Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood, 2022, 21, 285-289. DOI: 10.1182/blood.2022015832
COLLABORATION WITHIN THE NICR

Marek Mráz
(Brno node, CEITEC MU)

Michal Šmída
(Brno node, CEITEC MU)

Šárka Pospíšilová
(Brno node, Faculty of Medicine MU/CEITEC MU)

Vítězslav Bryja
(Brno node, Faculty of Science MU)

SPECIALIZED EXPERTISE AND TECHNOLOGY

Diagnosis and treatment of myeloid leukemias

Clinical trials

Mouse models

Single cell analysis

COLLABORATION WITH LARGE RESEARCH INFRASTRUCTURES AND RESEARCH CENTRES

The CzEch Leukemia Study Group – for Life CELL

Study Alliance Leukemia/AML Cooperative Group SAL

Universitätsklinikum Jena (Prof. Hochhaus, Germany)

Medizinische Universität Wien (Prof. Valent, Austria)